# **Special Issue**

# LCMV – A Pillar for Immunology Research

## Message from the Guest Editor

Since its original description by Charles Armstrong in 1934, lymphocytic choriomeningitis virus (LCMV) has been a useful instrument in the immunologists' toolbox. LCMV has been central to the discovery of a wide range of immunological concepts, both relevant to the antiviral host response and beyond. They include groundbreaking experiments by Rolf Zinkernagel and Peter Doherty that led to the discovery of MHC molecules and ultimately the concept of self tolerance, and Michael Oldstone's work on viral immunopathology and chronic infection. Likewise, the seminal works of Rafi Ahmed, E. John Wherry and many others to characterise functional T cell exhaustion laid the foundation for the development of new treatments for chronic infections and malignant diseases. There is no doubt that the study of LCMV will continue to open new avenues of research in immunology. The goal of this Special Issue is to assemble both reviews and original research manuscripts that focus on LCMV as both a model and pathogen to illuminate the diverse nature of anti-viral responses.

## **Guest Editor**

Dr. Markus J. Hofer

School of Life and Environmental Sciences, The University of Sydney, Sydney, Australia

## Deadline for manuscript submissions

closed (30 June 2019)



## **Viruses**

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/14214

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





# Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

### **Editor-in-Chief**

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

#### **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

## **Journal Rank:**

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

